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Background: It is recognized that hepatitis C virus subtypes (1a, 1b, 2a, 2b, 2c and 3a) origi-
nated in Africa and Asia and spread worldwide exponentially during the Second World War
(1940)  through the transfusion of contaminated blood products, invasive medical and dental
procedures, and intravenous drug use. The entry of hepatitis C virus subtypes into different
regions occurred at distinct times, presenting exponential growth rates of larger or smaller
spread. Our study estimated the growth and spread of the most prevalent subtypes currently
circulating in São Paulo.
Methods: A total of 465 non-structural region 5B sequences of hepatitis C virus covering a 14-
year  time-span were used to reconstruct the population history and estimate the population
dynamics and Time to Most Recent Common Ancestor of genotypes using the Bayesian
Markov Chain Monte Carlo approach implemented in BEAST (Bayesian evolutionary analysis
by  sampling tree software/program).
Results: Evolutionary analysis demonstrated that the different hepatitis C virus subtypes had
distinct growth patterns. The introduction of hepatitis C virus-1a and -3a were estimatedto  be circa 1979 and 1967, respectively, whereas hepatitis C virus-1b appears to have a more
ancient entry, circa 1923. Hepatitis C virus-1b phylogenies suggest that different lineages
circulate in São Paulo, and four well-supported groups (i.e., G1, G2, G3 and G4) were identiﬁed.
Hepatitis C virus-1a presented the highest growth rate (r = 0.4), but its spread became less
marked after the 2000s. Hepatitis C virus-3a grew exponentially until the 1990s and had an
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intermediate growth rate (r = 0.32). An evident exponential growth (r = 0.26) was found for
hepatitis C virus-1b between 1980 and the mid-1990s.
Conclusions: After an initial period of exponential growth, the expansion of the three main
subtypes began to decrease. Hepatitis C virus-1b presented inﬂated genetic diversity, and
its  transmission may have been sustained by different generations and transmission routes
other than blood transfusion. Hepatitis C virus-1a and -3a showed no group stratiﬁcation,
most likely due to their recent entry.
© 2015 Elsevier Editora Ltda. All rights reserved.Introduction
Hepatitis C virus (HCV) was identiﬁed by Choo et al. in 19891
and is currently a major cause of chronic hepatitis in the
world, reaching 150 million carriers (2–3% of the world pop-
ulation), with approximately 3–4 million new infections and
350,000 deaths annually.2 HCV is thought to have originated
in West Africa or Southern Asia, regions where endemic geno-
types remained for hundreds of years (between 500 and 1000
years), with relatively low transmission rates, mainly via inef-
ﬁcient routes, such as sexual or vertical transmission, and by
practices such as circumcision, excision, and scariﬁcation.3–8
Representatives from these endemic genotypes show high
genetic variation among strains and are found in restricted
geographic regions, including genotypes 1 and 4 in Central
Africa, 2 in West Africa, 5 and 7 in Central/Southern Africa,
and 3 and 6 on the Indian sub-continent and in South and East
Asia.6,7,9–12 Some subtypes of endemic regions have spread to
different regions and expanded globally. The epidemic sub-
types (1a, 1b, 2a, 2b, 2c, and 3a) then spread exponentially
during and after the Second World War (1940) when there was
an increase of very efﬁcient new ways of transmission, such
as the transfusion of contaminated blood and blood products,
invasive medical and dental procedures, and also intravenous
drug use (IVDU).13–15 In addition to their wide distribution
in the world, these subtypes are characterized by their high
prevalence and low genetic variation.3,16,17
The risk of HCV transmission via blood transfusion was
strikingly decreased after the introduction of anti-HCV sero-
logic screening tests for blood donors. Additionally, the
introduction of nucleic acid testing (NAT) for HCV screening
further reduced the risk of transfusion-transmitted HCV.18,19
In contrast, the use of intravenous drugs remains one of the
major risk factors for HCV infection,20 and sexual transmis-
sion, which generally showed low or inefﬁcient transmission
in the general population has also been associated with prac-
tices that lead to mucosal trauma and presence of ulcerative
genital diseases.21,22
In Brazil, the prevalence of HCV among drug users may
reach 36%.23–25 In the HIV co-infected population, it ranges
between 18% and 31%.26,27 In the general population, the
prevalence is approximately 1.5%28–30 and may vary from
0.19% to 1.2% in blood donors.31–36In São Paulo State (Brazil), a predominance of epidemic
subtypes is observed. HCV-1a corresponds to 32%–34.4% of all
infected subjects, while HCV-1b is detected in 36.2%–45.5%,
and HCV-3a in 18%–24.2%. Others genotypes such as 4 and 5are rarely detected.37–39 The entry of the different HCV sub-
types into São Paulo appears to have occurred on different
dates, and each subtype appears to have grown at distinct
rates.38,40,41 In this study, we sought to estimate the growth
and spread of the most prevalent subtypes and to investigate
the current situation of these subtypes in São Paulo.
Materials  and  methods
Study  population
Samples from two different studies were analyzed, compris-
ing a period of 14 years (1997–2011): 580 partial sequences of
the non-structural region 5B (NS5B) (IDs GQ490493–GQ491027)
of patients from São Paulo State38 and 170 partial sequences of
NS5B from blood donors of Fundac¸ão Pró-Sangue/Hemocentro
de São Paulo (IDs KF523955–KF524152).37 The ﬁrst study
included patients from four different cities of São Paulo
State (Ribeirão Preto, São José do Rio Preto, São Bernardo
do Campo, and from two reference centers for HCV surveil-
lance and treatment in São Paulo city) that were collected
between 1997 and 2006 (IDs GQ490493–GQ491027). The fre-
quency of major risk factors were 36% of blood transfusion
history, 18% injecting drug users, and 32% that did not dis-
close any risk factor.38 The second study was conducted in
blood donors screened from September 2007 to July 2011 in
São Paulo city and although considered to be a population with
low risk behavior 11% reported blood transfusion, 6% inject-
ing drug use, and 20% no risk factors associated with HCV
infection.37 The NS5B sequences were aligned using Clustal
X and genotyped by maximum likelihood analysis using the
GARLi program (Genetic Algorithm for Rapid Likelihood Infer-
ence). From this, three distinct datasets containing only São
Paulo sequences were built, HCV-1a (n = 98), HCV-1b (n = 218)
and HCV-3a (n = 149), to investigate the population history of
the samples. Other sequences were removed from the study.
Additionally, a dataset containing 70 non-structural region 3
(NS3) sequences (708 nucleotides long) generated in the same
study from HCV-1b-infected blood donors was constructed for
further analysis (IDs KF524133–KF524257).
HCV  phylodynamicsThe population dynamics and TMRCA (Time to Most Recent
Common Ancestor) for the three genotypes were investi-
gated using the Bayesian Markov Chain Monte Carlo (MCMC)
approach implemented in the BEAST v 1.8 package.42 The least
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Table 1 – HCV subtypes and subgroup Time to Most
Recent Common Ancestor (TMRCA) and rate of
population growth.
Subtype Samples (n) TMRCA (upper and lower) Growth
rate (r)
1a 98 1979 (1967–1987) 0.4
3a 149 1967 (1955–1980) 0.32
1b all 218 1923 (1844–1967) 0.26
1b G1 79 1966 (1947–1981) 0.3
1b G2 90 1972 (1959–1983) 0.4
1b G3 6 1983 (1975–1991) –
1b G4 36 1973 (1955–1985) 0.26
TMRCA, Time to Most Recent Common Ancestor; r, rate of popula-
tion growth.b r a z j i n f e c t d i s .
onstrained Bayesian skyride (BSK) coalescent was used as
 tree prior under a relaxed (uncorrelated) molecular clock
ith the best model of nucleotide substitution (GTR + G + I)
stimated in MODELTEST.43 The substitution rate was set as
reviously estimated for each genotype.38 MCMC runs con-
isting of 50 million generations (with 10% burn-in) were
ndertaken to obtain parameter convergence. A maximum
lade credibility (MCC) tree was obtained by summarizing the
0,000 trees with branch lengths of nucleotide substitution
after excluding 10% of the burn-in) using Tree Annotator
.1.7.2.42 The phylogenetic trees were visualized in FigTree
.1.2.2 (available at: http://tree.bio.ed.ac.uk/software/ﬁgtree).
We  also aimed to estimate the rate of population growth (r)
nder the demographic model (exponential and logistic pop-
lation growth) that best ﬁt each subtype dataset, with model
omparisons undertaken using Bayes Factor comparison. In all
ases, the convergence of parameters during the MCMC runs
as inspected with Tracer v.1.4,42 with uncertainties depicted
s 95% highest probability (HPD) intervals.
Potential risk factors involved in HCV transmission such
s a history of blood transfusion, tattooing, intravenous drug
se, occupational exposure, and sexual behavior were ana-
yzed in addition to demographics such as age, sex, race, and
ducation.
tatistical  analysis
he characteristics were evaluated according to the subgroups
elonging to subtype 1b of blood donors. To compare the G1-G4
ubgroups according to some demographic characteristics and
elated risk behaviors, we  used chi-squared test of signiﬁcance
evel of 5%.
esults
e  analyzed partial sequences of the NS5B gene belonging
o the most prevalent subtypes in our population, subtypes
a, 1b and 3a. After genotyping using worldwide sequences
s references, we  excluded all taxa that clustered with sam-
les from outside Brazil. This was performed to reduce the
ffect of any phylogeographic structure on the further analy-
is of the transmission dynamics. By including only ‘Brazilian’
equences, the evolutionary analysis demonstrated that the
ifferent subtypes have distinct growth patterns, as demon-
trated by the tree shapes, and also conﬁrmed the previous
bservation that they were introduced into São Paulo at dif-
erent times. The TMRCAs for HCV-1a and -3a were estimated
o be circa 1979 and 1967, respectively, and HCV-1b appeared
o have a more  ancient entry, circa 1923, which is very similar
o the previous estimate38 (Table 1).
Different from what the HCV-1a phylogeny suggests, the
CV-3a and HCV-1b phylogenies indicate that different lin-
ages circulated in São Paulo (Fig. 1). However, although
o support was observed for HCV-3a lineages, four well-
upported groups, named Groups 1–4 (i.e., G1, G2, G3 and G4)
ere identiﬁed for HCV-1b (Fig. 1). To verify the consistency
f the HCV-1b subgroups, we investigated the phylogenetic
attern of this subtype using the NS3 sequences obtained
rom the same samples generated in this study. Similar to theThe growth rate was not estimated for G3 because it includes only
six sequences.
structure obtained for the NS5 gene, NS3 also depicted four
well-supported groups (Fig. 1).
Because the observed groups were very consistent in both
phylogenies (NS5B and NS3), we also estimated the time of
their emergence. Assuming as a prior the same evolutionary
rate for all subgroups and using the NS5 dataset, we  found
that the subgroups did not differ signiﬁcantly according to
their emergence in São Paulo (because upper and lower val-
ues overlapped each other). Nevertheless, the median values
suggested that Group 1 was the ﬁrst to spread in this popula-
tion (late 1960s), followed by Groups 2 and 4, which emerged
at the same time around the beginning of the 1970s (Table 1).
These subgroups (G1–G4) were not associated with gender,
age, ethnicity, or education level, and there was no association
between the subgroups and the different exposure categories,
except for G2, which had entered in 1972 and was associated
with a history of blood and blood product transfusion in 62.5%
(5/8; p = 0.043) of the carriers.
We  also estimated the growth rate for HCV-1a, -1b (total and
subgroups) and -3a using BEAST (Bayesian evolutionary anal-
ysis by sampling tree software/program) based on the best-ﬁt
demographic model for each NS5 dataset. The exponential
growth model under the exponential relaxed (uncorrelated)
molecular clock was the best for all datasets according to Bayes
Factor. HCV-1a presented the highest growth rate among the
subtypes (r = 0.4), but accordingly to the skyride plot (Fig. 1), the
spread has become less marked after the 2000s. HCV-3a, which
is likely to have entered São Paulo some years before HCV-1a,
grew exponentially until 1990 and had an intermediate growth
rate (0.32) in comparison to HCV-1a and -1b (Table 1). The
HCV-1b skyride clearly showed an evident exponential growth
between 1980 and the mid-1990s, as already demonstrated by
others.15,38
Discussion
HCV-3a and -1b display multiple lineages in São Paulo, indi-
cating the simultaneous dissemination of multiple strains.
However, only the HCV-1b lineages are well supported. HCV-
1b showed four distinct subgroups, herein named G1 to G4, in
accordance with the studies of Lampe et al.,41 who found ﬁve
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Fig. 1 – (A) HCV-1a and (B) HCV-3a MCC  trees showing the classical star-shaped phylogenies. (C) HCV-1b MCC  tree showing
four well-supported groups named Groups 1–4. (D) Skyride plot showing the population dynamics and TMRCA for the NS5B
HCV region of subtypes 1a, -1b and -3a. MCC, maximum clade credibility; TMRCA, time to most recent common ancestor.subgroups of subtype 1b. Interestingly, Lampe et al.41 found
that those lineages were associated with geographical location
(western and southeast regions of Brazil), and our sequences
obtained from São Paulo also reﬂect such genetic isolation.
Although no evident association between clinical or epidemi-
ological relationships for such groups was found, we speculate
that these lineages circulated within particular transmission
groups restricted by factors yet to be determined. There was
also no association between subgroup 1b and age, and the
most likely hypothesis is that the circulation of these lineages
occurred over a long period from the beginning of the 20th cen-
tury (oldest subtype), which could have resulted in a “dilution”
in the transmission of this subtype for different risk groups
and different age groups. Unlike HCV-1a, the latest entry in
our population showed a similar transmission within groups
that share the same habits and the same age group.38 The data
presented in this work appear to be robust because they are
consistent with previous estimates that used sequences com-
prising a shorter time span (nine years). The larger number of
sequences as well the time span (14 years) did not alter thegrowth rates or coalescent times of the main HCV subtypes in
São Paulo.
In fact, the ﬁndings for HCV-1b (especially the periods
of exponential growth and decrease) coincide with histori-
cal events such as the foundation of the ﬁrst blood bank
and improvements in blood transfusion services, 1940–1960,44
and the simultaneous increase in medical procedures such
as hemodialysis in 1960.45 Conversely, measures to prevent
transmissible agents in blood, such as hepatitis B virus and
human immunodeﬁciency virus, in the late 1980s and the
obligatory serological screening in blood banks for HCV in 1993
contributed to the reduction and stabilization of the epidemic
after 1990. The observed pattern of expansion is very similar
to that found by Magiorkinis et al.15 in the USA, where subtype
1b showed a TMRCA of 1922 and an exponential increase. After
the Second World War, transfusions and invasive medical pro-
cedures as well as therapeutic injections were widespread
until the 1980s. At this time, an increased awareness of par-
enteral risk and the selection and screening of blood donors for
HBsAg, ALT, anti-HBc, and anti-HIV resulted in the reduction of
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he risk of HCV transmission, even before the implementation
f the anti-HCV test in 1990.19
Although introduced more  recently than the subtype -1b,
CV-3a spread exponentially until 1990; the worldwide sub-
ype 3a epidemic most likely began in the mid-20th century,
ad a common origin and quickly spread globally among drug
sers.46,47 Some studies have associated genotype 3 with IVDU
nd also with the use of stimulant medications (IV non-illicit
rugs such as Gluconergan) in the 1970s.48 The association
ith these groups would most likely explain the high fre-
uency of this subtype in the older group (>40 years) in this
opulation.37 The decline in needle sharing and the frequency
f injections and increasing educational measures might have
ontributed to reducing this risk of parenteral exposure in the
arly 1990s.49
HCV-1a was found to be the most recently introduced
ubtype in our region and showed the highest growth rate
ompared with other subtypes. Unlike subtype 1b that had
 decline of the spread after mandatory serological screening
or HBV, HIV, and HCV at the end of the 1980s in Brazilian blood
anks, subtype 1a showed an increase in the spread as demon-
trated in exponential expansion curve (in Skyride plot) in the
id-1990s, which continued until 2005. So, the main route of
CV-1a transmission is probably not blood transfusion, but
DIV.
Some authors have associated subtype 1a with the use
f intravenous drugs,15,40,48,49 and even young individuals or
hort-time drug users (recent) could be more  associated with
eedle sharing and contributing to the spread of this subtype
a in this age group.24,50 This is in accordance with an increase
n the frequency of subtype 1a among younger donors (<30
ears).37
Our data clearly show that after an initial period of expo-
ential growth, the expansion of the three main subtypes
egan to decrease as a consequence of the introduction of anti-
CV screening tests and political and educational measures
voiding needle sharing among IVDUs. The delay observed in
SK for HCV-1b decline appears to be the consequence of two
ossible and non-exclusive hypotheses: (i) the inﬂated genetic
iversity in the tree caused by the concomitant circulation of
t least four monophyletic strains, and (ii) as HCV-1b is the
ost ancient and most prevalent subtype in São Paulo, where
t was ﬁrst spread by transfusion route and its transmission
as sustained by different generations through routes that
llowed spread of 4 lineages (G1–G4) forming groups restricted
y factors yet to be determined. HCV-1a and -3a showed low
enetic variation, in accordance with their recent entry.
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